Edaravone Injection
- Packing: 20 Ml Ampoule.
- Available Strength : 1.5 Mg/Ml
Description
Product Description: Edaravone Injection is a meticulously formulated pharmaceutical solution designed to mitigate oxidative stress and neuroinflammation in patients with amyotrophic lateral sclerosis (ALS). It contains edaravone, a potent free radical scavenger and antioxidant known for its neuroprotective properties. Manufactured to the highest quality standards, this injection offers targeted therapy for slowing the progression of ALS and improving the quality of life for affected individuals.
Indications and Usage: Edaravone Injection is indicated for the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disorder affecting motor neurons in the brain and spinal cord. It is used to slow the progression of functional impairment in patients with ALS and to delay the need for invasive respiratory support.
Dosage and Administration: The dosage of Edaravone Injection is 60 mg administered via intravenous infusion over 60 minutes once daily. Treatment duration consists of cycles, with each cycle lasting 14 days followed by a 14-day drug-free period. The infusion rate should be adjusted based on patient tolerance, and the entire course of treatment should be supervised by a qualified healthcare professional.
Dosage Forms and Strengths: Edaravone Injection is available as a sterile solution in vials containing 30 mg/20 mL (1.5 mg/mL) of edaravone. Each vial is carefully manufactured to ensure accurate dosing and optimal therapeutic outcomes.
Contraindications: This product is contraindicated in patients with a known hypersensitivity to edaravone or any of the excipients. It should not be used in patients with hereditary fructose intolerance due to the presence of sorbitol in the formulation. Additionally, it is contraindicated in pregnant women and nursing mothers.
Warnings and Precautions: Healthcare providers should monitor patients receiving Edaravone Injection for signs of hypersensitivity reactions, including anaphylaxis, rash, and respiratory distress. Liver function tests should be conducted regularly due to the potential for liver enzyme elevations. Patients with a history of asthma may be at increased risk of bronchospasm.
Adverse Reactions/Side Effects: Common adverse reactions associated with Edaravone Injection include bruising, gait disturbance, and headache. Infusion site reactions, such as erythema and pain, may also occur. Less common adverse effects include hypersensitivity reactions, liver enzyme elevations, and respiratory disorders. Patients should be advised to report any unusual symptoms promptly.
Drug Interactions: There are no known drug interactions with Edaravone Injection. However, caution should be exercised when coadministering with other drugs that may prolong the QT interval or increase the risk of hepatic injury.
Use In Specific Populations Description: Safety and efficacy of Edaravone Injection in pediatric patients, pregnant women, and nursing mothers have not been established conclusively. Healthcare providers should assess the potential risks and benefits before prescribing this medication in these populations.
How Supplied/Storage and Handling: Edaravone Injection is supplied as a sterile solution in vials for intravenous infusion. It should be stored at controlled room temperature (20°C to 25°C) away from light and moisture. Care should be taken to avoid freezing or excessive heat exposure. Unused portions should be discarded according to standard procedures for biohazardous waste.
